Ken Griffin An2 Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 67,994 shares of ANTX stock, worth $82,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,994Holding current value
$82,952% of portfolio
0.0%Shares
8 transactions
Others Institutions Holding ANTX
# of Institutions
38Shares Held
13.8MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$7.01 Million4.93% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.31MShares$1.6 Million0.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.26 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY581KShares$708,6400.89% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny580KShares$707,3230.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $23.7M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...